{"entity":{"id":"nct03843918","kind":"trial","name":"A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer","aka":[],"tldr":"A phase 1/2 trial of Lapiteronel run by Laekna Limited, terminated.","summary":"A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT03843918 by Laekna Limited, with 33 participants enrolled, started 2019-04-05, primary completion reached 2023-10-09. Conditions recorded: Prostate Cancer Metastatic. Interventions recorded: LAE001. Reason given for stopping: This is phase I/II study, phase I study completed, phase II study started and enrolled 1 patient. Company strategy consideration to terminated phase 2 study finally.","status":"historic","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT03843918","url":"https://clinicaltrials.gov/study/NCT03843918"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["lapiteronel"],"companies":["laekna-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03843918","phase":"1/2","setting":"A Phase I/II Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer","sponsor":"Laekna Limited","enrolled":33,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03843918/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"lapiteronel","kind":"drug","name":"Lapiteronel","route":"/drugs/lapiteronel/"}],"company":[{"id":"laekna-therapeutics","kind":"company","name":"Laekna Therapeutics","route":"/companies/laekna-therapeutics/"}]}}